Welcome to our dedicated page for Iterum Therapeutics Plc SEC filings (Ticker: ITRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Iterum Therapeutics’ latest disclosures but buried under technical jargon? Clinical-stage biotech reports are packed with trial statistics, FDA discussions, and cash-runway math that can stretch well past 250 pages. For investors tracking antibiotic innovators, missing a single footnote could mean overlooking a pivotal clinical milestone or dilution warning.
Stock Titan solves that problem. Our AI reads every Iterum Therapeutics quarterly earnings report 10-Q filing, Iterum Therapeutics annual report 10-K simplified, and Iterum Therapeutics 8-K material events explained in real time, then delivers plain-English summaries of R&D spend, Fast Track designations, and trial results. Need to monitor Iterum Therapeutics insider trading Form 4 transactions? Receive alerts on Iterum Therapeutics Form 4 insider transactions real-time so you instantly see when executives buy or sell shares.
Every document type is covered:
- 10-K & 10-Q: cash runway, pipeline updates, risk factors—Iterum Therapeutics SEC filings explained simply
- 8-K: outcome of Phase 3 studies, FDA feedback
- DEF 14A: Iterum Therapeutics proxy statement executive compensation tied to clinical milestones
- Form 4: Iterum Therapeutics executive stock transactions Form 4 for insider sentiment
With our AI-powered summaries, you’ll quickly access Iterum Therapeutics earnings report filing analysis, compare quarter-over-quarter R&D trends, and assess how new data might impact valuation—all without combing through endless pages. Stay informed with comprehensive coverage, real-time updates, and expert context that turns dense biotech filings into actionable insights.
Iterum Therapeutics plc filed a prospectus supplement to sell up to $20,000,000 of ordinary shares in an at-the-market program through H.C. Wainwright & Co., not to exceed 21,756,057 ordinary shares. Sales may be made on the Nasdaq Capital Market or by other permitted methods, with Wainwright acting as sales agent.
The program is limited to the company’s authorized but unissued share capacity. Based on 21,756,057 shares currently available for issuance and an assumed price of $0.7377, the company indicates it could sell up to approximately $16,049,443 under the agreement. Iterum will pay a 3.0% sales commission to Wainwright and would receive the net proceeds.
This supplement supersedes the prior ATM supplement, moving the remaining $4,775,345 capacity under that document into this one. Iterum reports aggregate gross proceeds of approximately $36.2 million previously raised under the sales agreement. Ordinary shares outstanding were 48,051,157 as of September 15, 2025. The shares trade on Nasdaq as “ITRM.”
Iterum Therapeutics (ITRM) filed a prospectus supplement to sell ordinary shares from time to time under its existing at‑the‑market program, targeting additional aggregate gross proceeds of up to $20,000,000, not to exceed 21,756,057 shares, through H.C. Wainwright & Co. as sales agent.
The company previously sold approximately $36.2 million of shares under the same Sales Agreement and earlier prospectuses. Iterum also noted it commercially launched ORLYNVAH™ in the U.S. community market in August 2025 and expects modest sales in 2025 during the early commercialization phase.
Michael W. Dunne, a director of Iterum Therapeutics plc (ITRM), filed a Form 4 reporting a transaction on 08/08/2025. The filing shows a reported acquisition of 15,000 ordinary shares at $0.7236. Following the transaction, Mr. Dunne beneficially owned 235,001 shares on a direct basis. The Form 4 bears his signature dated 08/12/2025.
FAQ
What is the current stock price of Iterum Therapeutics Plc (ITRM)?
What is the market cap of Iterum Therapeutics Plc (ITRM)?
